Clinical Pharmacokinetics of 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)methyl]cytosine in Human Immunodeficiency Virus-Infected Patients

The pharmacokinetics and bioavailability of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine (cyclic HPMPC) were examined at four doses in 22 patients with human immunodeficiency virus infection. Two groups of six patients received a single dose of cyclic HPMPC at 1.5 or 3.0 mg/k...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cundy, Kenneth C., Barditch-Crovo, Patricia, Petty, Brent G., Ruby, April, Redpath, Murphy, Jaffe, Howard S., Lietman, Paul S.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 1999
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC89062/
https://ncbi.nlm.nih.gov/pubmed/9925517
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares